Please sign in to follow a disease.
Progressive muscular dystrophy
MONDO:0016106Also known as: progressive muscular dystrophy
127 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 09, 2026 17:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control CompletedThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for FSHD: experimental drug AOC 1020 completes early testing
Disease control CompletedThis study tested a new medicine called AOC 1020 in 90 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. The goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a p…
Phase 1/2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedThis study tested a new drug called AOC 1001 in 39 adults with myotonic dystrophy type 1, a genetic muscle disorder. Participants received either the drug or a placebo by IV infusion. The goal was to check safety and how the drug moves through the body. Results will help decide i…
Phase 1/2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug PGN-EDODM1 tested for muscle disease
Disease control CompletedThis early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.
Phase 1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug shows promise for rare muscle disease in kids
Disease control CompletedThis study tested a drug called tideglusib against a placebo in 56 children aged 6 to 16 with congenital myotonic dystrophy, a rare genetic muscle disorder. The goal was to see if tideglusib could reduce symptoms like muscle weakness and breathing problems. The trial was complete…
Phase 2/3 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis phase 2 study tested the safety and effectiveness of tideglusib, an experimental drug, in 16 adolescents and adults with congenital or juvenile-onset myotonic dystrophy type 1. Participants received either 400 mg or 1000 mg of tideglusib daily. The study measured side effect…
Phase 2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
AI spots rare muscle disease from a simple video
Diagnosis CompletedThis completed pilot study tested whether a computer algorithm could diagnose facioscapulohumeral muscular dystrophy (FSHMD) by analyzing video recordings of people's faces. Researchers recorded 17 participants, including patients with FSHMD, other muscle diseases, and healthy co…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New blood test could replace risky prenatal procedures for genetic diseases
Diagnosis CompletedThis study aimed to develop a non-invasive prenatal test using fetal cells from a mother's blood to detect triplet repeat diseases like Huntington's disease, Fragile X syndrome, and certain types of muscular dystrophy and ataxia. Researchers enrolled 60 pregnant women at risk and…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Can a wakefulness drug combat the crushing fatigue of myotonic dystrophy?
Symptom relief CompletedThis phase 2 trial tests whether pitolisant, a wake-promoting drug, can reduce excessive daytime sleepiness in adults aged 18 to 65 with myotonic dystrophy type 1. Participants receive either pitolisant or a placebo for a period, and researchers measure changes in sleepiness, fat…
Phase 2 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New fabric brace could give arm strength back to patients with muscle diseases
Symptom relief CompletedThis study tests a special fabric shoulder brace designed to mimic muscle support for people with neuromuscular disorders like muscular dystrophy, SMA, and ALS. About 30 participants will wear the brace and perform arm tasks to see if it improves movement, strength, and daily fun…
Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Could virtual reality help kids with a rare muscle disease read emotions better?
Symptom relief CompletedThis study tests whether virtual reality training can help children aged 6 to 16 with the childhood form of myotonic dystrophy type 1 (DM1) improve their ability to understand others' thoughts and emotions. Participants engage in social scenarios in a virtual environment, guided …
Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New study tracks Long-Term safety of muscle stiffness drug namuscla
Symptom relief CompletedThis study followed 53 adults with non-dystrophic myotonic disorders who were taking Namuscla (mexiletine) to manage muscle stiffness. Researchers monitored side effects and how often patients needed to reduce their dose or stop treatment over up to 36 months. The goal was to see…
Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
How much protein do FSHD patients really need? new study aims to find out
Knowledge-focused CompletedThis study looks at how much protein adults with facioscapulohumeral muscular dystrophy (FSHD) need each day to support muscle health. Researchers will test different amino acid intakes in 10 participants using a non-invasive technique. The goal is to improve dietary recommendati…
Sponsor: McGill University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Tiny study probes muscle oxygen in rare nerve and muscle diseases
Knowledge-focused CompletedThis completed study looked at how muscle oxygen levels change during exercise in people with various neuromuscular diseases compared to healthy volunteers. Seventeen participants did a knee-extension exercise while a device measured muscle oxygen. The goal was to understand diff…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Inflammation may be key in rare muscle disease
Knowledge-focused CompletedThis pilot study examined whether inflammation, measured by cytokines in the blood, plays a role in type 1 facioscapulohumeral muscular dystrophy (FSHD1). Researchers compared 20 FSHD1 patients with healthy controls to see if certain inflammatory markers are higher in the disease…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Heart risk study for muscular dystrophy patients completed
Knowledge-focused CompletedThis study looked at 537 people with myotonic dystrophy type 1 to understand their risk of serious heart rhythm problems, including sudden cardiac arrest. Researchers tracked participants for two years to see how often these events happened and what factors might predict them. Th…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New tool could better track facial muscle health in rare muscle disease
Knowledge-focused CompletedThis study tested a new method to evaluate the strength and function of face and mouth muscles in people with facioscapulohumeral muscular dystrophy (FSHD). Twenty-two adults with a genetic diagnosis of FSHD took part. The goal was to see if this new assessment tool can reliably …
Sponsor: University of Mons • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study maps key tests for LGMD to speed up drug development
Knowledge-focused CompletedThis study involved 116 people with Limb Girdle Muscular Dystrophy (LGMD), a group of rare muscle-weakening disorders. Researchers measured how well participants could walk, move their arms, and breathe, and asked about their daily activities and overall health. The goal was to i…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New app could help track muscle disease from your living room
Knowledge-focused CompletedThis study tested whether a mobile app (myFSHD) can help doctors monitor patients with facioscapulohumeral muscular dystrophy (FSHD) remotely. 70 adults with FSHD used the app at home for 12 months, completing questionnaires and video-recorded exercises. The goal was to see if pa…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New study tracks muscle decline in rare disease to guide future treatments
Knowledge-focused CompletedThis study followed 52 people with limb-girdle muscular dystrophy 2I (LGMD2I) for up to two years to learn more about how the disease changes over time. Researchers measured walking ability, muscle strength, heart function, and daily activities. The goal was to better understand …
Sponsor: Genethon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to sharpen tools for measuring muscle decline in common adult muscular dystrophy
Knowledge-focused CompletedThis study followed 30 adults with myotonic dystrophy type 1 (Steinert disease) and 30 healthy volunteers over three years to see how muscle strength and function change naturally over time. Researchers measured things like muscle power, walking ability, and nerve responses to fi…
Sponsor: Institut de Myologie, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Sound waves could spot early signs of rare muscle disease
Knowledge-focused CompletedThis study tested whether ultrasound can detect early facial muscle changes in people with facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disease. Researchers compared 20 FSHD patients with 19 healthy adults, measuring muscle thickness and echo intensity in key faci…
Sponsor: Koç University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study aims to uncover why some myotonic dystrophy patients develop low breathing
Knowledge-focused CompletedThis study followed 113 adults with myotonic dystrophy (Steinert's disease) for 5 years to find out what factors lead to low breathing (hypoventilation). Researchers measured lung function, sleepiness, fatigue, and thinking skills. The goal is to better understand which patients …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Hidden danger: muscle disease linked to deadly clots
Knowledge-focused CompletedThis study investigates why people with myotonic dystrophy type 1 are 10 times more likely to develop dangerous blood clots in the legs or lungs. Researchers will compare blood samples from 130 participants—including patients with the disease, those with a history of clots, and h…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:53 UTC